All In Biotech

NDA 207960 · Nextwave Pharms

Quillichew Er

Methylphenidate Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Dec 4, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

456

101 Phase 3, 37 recruiting

FAERS reports

7,501

4,385 serious, 443 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE AND ADDICTION QuilliChew ER has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including QuilliChew ER, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing QuilliChew ER, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout QuilliChew ER treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) and Drug Abuse and Dependence (9.2) ] . WARNING: ABUSE,...

What it is approved for

From the label in effect Apr 8, 2026.

QuilliChew ER is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies ( 14 ) ]. Limitations of Use The use of QuilliChew ER is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ) , Use in Specific Populations ( 8.4 ) ]. QuilliChew ER is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). ( 1 ) Limitations of Use The use of QuilliChew ER is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).

Mechanism: Methylphenidate is a central nervous system (CNS) stimulant.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • QUILLICHEW ER · METHYLPHENIDATE HYDROCHLORIDE 30MG · TABLET, EXTENDED RELEASE, CHEWABLE, ORAL · Prescription
  • QUILLICHEW ER · METHYLPHENIDATE HYDROCHLORIDE 40MG · TABLET, EXTENDED RELEASE, CHEWABLE, ORAL · Prescription
  • QUILLICHEW ER · METHYLPHENIDATE HYDROCHLORIDE 20MG · TABLET, EXTENDED RELEASE, CHEWABLE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.

All 456 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,187
  • headache417
  • off label use395
  • anxiety374
  • fatigue361
  • nausea342
  • toxicity to various agents333
  • product substitution issue295
  • drug abuse285
  • insomnia277
  • somnolence275
  • decreased appetite252

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20061
20073
20088
200918
201014
201118
201269
2013117
2014121
2015440
2016375
2017529
2018786
2019508
2020375
2021434
2022645
2023811
2024763
2025755
2026708

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Quillichew ER (Methylphenidate HCl)

2024 spending

$285K

Beneficiaries

110

644 claims

Per beneficiary

$2,591

$12.47 per unit

View as table
YearSpending
2020$135,704
2021$185,194
2022$201,077
2023$260,316
2024$285,029

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,058 on PubMed

Sponsor: Nextwave Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.